Focal Segmental Glomerulosclerosis, Glomerulonephritis
Conditions
Keywords
focal segmental glomerulosclerosis, disease progression
Brief summary
Focal segmental glomerulosclerosis (FSGS) is one of the most common primary glomerular diseases leading to end stage renal disease. In this study, our aim is to evaluate the effects of histopathological, clinical, and laboratory features of patients with primary FSGS on the disease progression.
Detailed description
Focal segmental glomerulosclerosis (FSGS) is one of the most common primary glomerular diseases leading to end stage renal disease worldwide. Numerous studies have been conducted in order to identify the etiology of this debilitating disease. Beyond the etiological research, however, few studies managed to demonstrate the possible predictors of disease progression in patients. Therefore, we aim to evaluate the effects of histopathological, clinical, and laboratory features of patients with primary FSGS on the disease progression.
Interventions
None listed
Sponsors
Istanbul University
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients with biopsy-proven primary focal segmental glomerulosclerosis. * Patients who have a renal biopsy available for reviewing including 8 or more glomeruli. * Patients who have been followed-up for at least 6 months or have progressed to primary outcome regardless the duration of follow-up.
Exclusion criteria
* Patients who have secondary focal segmental glomerulosclerosis attributable to any other condition (e.g., obesity, HIV, relevant drug exposure). * Patients who have a genetic mutation or variation creating a tendency for developing focal segmental glomerulosclerosis. * Patients who are unwilling or unable to consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Reduction in kidney function and/or progression to end stage renal disease | 5-10 years | At least a fifty-percent reduction in baseline estimated glomerular filtration rate (eGFR) or development of kidney failure, which was defined as a category G5 CKD (eGFR \<15 ml/min/1.73 m2). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Complete remission | 5-10 years | Proteinuria below 0.5 g/24h and an eGFR of ≥60 ml/min per 1.73 m2 (or a return of ±15% of baseline values in those with eGFR \<60 ml/min per 1.73 m2). |
| Partial remission | 5-10 years | Absence of complete remission, proteinuria reduction of \>50% (and a proteinuria value of \<3 g/24h in patients with nephrotic range proteinuria at baseline), and stabilization (±25%) or improvement in renal function. |
Countries
Turkey (Türkiye)
Outcome results
None listed